These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 33788182)

  • 1. Ocular Toxicity of Targeted Anticancer Agents.
    Fortes BH; Tailor PD; Dalvin LA
    Drugs; 2021 May; 81(7):771-823. PubMed ID: 33788182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020.
    Liang X; Yang Q; Wu P; He C; Yin L; Xu F; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B
    Bioorg Chem; 2021 Aug; 113():105011. PubMed ID: 34091289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
    Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
    Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
    Hojjat-Farsangi M
    Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
    Ruiz-Camps I; Aguilar-Company J
    Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Companion biomarkers: paving the pathway to personalized treatment for cancer.
    Duffy MJ; Crown J
    Clin Chem; 2013 Oct; 59(10):1447-56. PubMed ID: 23656699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy for advanced breast cancer.
    Rugo HS
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
    Ohno S
    Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the human kinome for cancer therapy.
    Daly RJ
    Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
    [No Abstract]   [Full Text] [Related]  

  • 11. [Ocular side effects of modern oncological therapy : Immunological checkpoint and MEK/BRAF signal transduction inhibitors].
    Thurau S; Wildner G; Gamulescu MA
    Ophthalmologie; 2023 May; 120(5):559-573. PubMed ID: 37160621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH; Liou H; Dalvin LA
    Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Management of Advanced Non-Small Cell Lung Cancer.
    Yang CY; Yang JC; Yang PC
    Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ALK, ROS1, and BRAF kinases.
    Doebele RC; Camidge DR
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S375-6. PubMed ID: 23160323
    [No Abstract]   [Full Text] [Related]  

  • 15. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer.
    Zabransky DJ; Park BH
    J Clin Oncol; 2014 Apr; 32(10):1084-6. PubMed ID: 24590645
    [No Abstract]   [Full Text] [Related]  

  • 16. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
    Asmussen J; Lasater EA; Tajon C; Oses-Prieto J; Jun YW; Taylor BS; Burlingame A; Craik CS; Shah NP
    Cancer Discov; 2014 Feb; 4(2):200-15. PubMed ID: 24362263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.
    Singleton KR; Kim J; Hinz TK; Marek LA; Casás-Selves M; Hatheway C; Tan AC; DeGregori J; Heasley LE
    Mol Pharmacol; 2013 Apr; 83(4):882-93. PubMed ID: 23371912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular effects of aromatase inhibitors: data from clinical trials.
    Howell A; Cuzick J
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapy for gastrointestinal cancer.
    Wiedmann MW; Caca K
    Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events of targeted anticancer therapies: what radiologists need to know.
    López Sala P; Alberdi Aldasoro N; Unzué García-Falces G
    Radiologia (Engl Ed); 2020; 62(3):229-242. PubMed ID: 32057481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.